Follow-Up Commentary on Selected Picks: (NASDAQ: CLDX), (NYSE: PC)
Celldex Therapeutics, Inc. (NASDAQ:CLDX) presented final results from a Phase 1 study of CDX-301 (recombinant human Flt3L; rhuFlt3L) in healthy volunteers that strongly support the initiation of a pilot study in hematopoietic stem cell transplantation later this year.
View full press release